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Abstract
Introduction: To study the pre-design and success of a strategy based on the addition of hemoglobin A1c (HbA1c) in the blood samples of certain 
primary care patients to detect new cases of type 2 diabetes.
Materials and methods: In a first step, we retrospectively calculated the number of HbA1c that would have been measured in one year if HbA1c 
would have been processed, according to the guidelines of the American Diabetes Association (ADA). Based on those results we decided to prospecti-
vely measure HbA1c in every primary care patient above 45 years, with no HbA1c in the previous 3 years, and glucose concentration between 5.6-6.9 
mmol/L, during an 18 months period. We calculated the number of HbA1c that were automatically added by the LIS based on our strategy, we eva-
luated the medical record of such subjects to confirm whether type 2 diabetes was finally confirmed, and we calculated the cost of our intervention.
Results: In a first stage, according to the guidelines, Hb1Ac should have been added to the blood samples of 13,085 patients, resulting in a cost of 
14,973€. In the prospective study, the laboratory added Hb1Ac to 2092 patients, leading to an expense of 2393€. 314 patients had an HbA1c value 
≥ 6.5% (48 mmol/mol). 82 were finally diagnosed as type 2 diabetes; 28 thanks to our strategy, with an individual cost of 85.4€; and 54 due to the 
request of HbA1c by the general practitioners (GPs), with a cost of 47.5€. 
Conclusion: The automatic laboratory-based strategy detected patients with type 2 diabetes in primary care, at a cost of 85.4€ per new case. 
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Hemoglobin A1c (HbA1c) has traditionally been 
used for the follow-up and management of pa-
tients with type 2 diabetes. It was not until 2010, 
when the American Diabetes Association (ADA) 
proposed its role as a tool to diagnose the disease 
(1). Indeed, the guidelines (2) recommend the test 
to screen asymptomatic adults of any age with 
overweight, obesity or any additional risk factor 
for type 2 diabetes. Additionally, in absence of 
these risks factors, HbA1c analysis should be per-
formed in patients above 45 years old. If the initial 
HbA1c value is < 6.5% (48 mmol/mol), the test 
should be repeated at least every 3 years (2,3); if 
the first test is above that cut-off an additional test 
is needed to confirm the disease (2).
Given the relatively recent role of HbA1c as a diag-
nostic tool (2,4-6), and the existing high variability 
in the test requesting (7-10) it seems necessary to 
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establish algorithms to improve its use. Indeed, re-
cent evidence indicates that HbA1c is significantly 
under-requested in Spain (11). Although there are 
additional tools for the diagnosis of the disease as 
oral glucose tolerance test and random plasma 
glucose measurement, a low HbA1c requesting 
could contribute to poor diagnosis and manage-
ment of type 2 diabetes (11). In fact some studies 
to identify occult diabetes through community 
screening strategies reported in the literature, 
show a success in detection and a cost per new 
case of diabetes ranging from 94.6€ ($100) to 
700.8€ ($741) (12-16).  
The overall role, and specific potential benefits 
and drawbacks of HbA1c as a diagnostic parame-
ter are largely unknown. We hypothesized that 
common availability of blood samples in the clini-
cal laboratory presented an opportunity to identi-
fy subjects with type 2 diabetes. This appeared 
feasible since HbA1c is stable and can be meas-
ured in the same samples that are used for hema-
tological testing. Furthermore, analysis of samples 
that are already available in the laboratory avoids 
the major costs of blood collection, transporta-
tion, and logging into an information system (17). 
We presumed that an algorithm to identify sam-
ples appropriate to be tested for HbA1c in primary 
care patients would detect new cases of type 2 di-
abetes.
The aim of the present research is first to present a 
completely automated strategy designed in the 
clinical laboratory in collaboration with general 
practitioners (GPs) based on the addition of HbA1c 
in the blood samples of certain primary care pa-
tients to detect new cases of type 2 diabetes; and 
second to study the success of such algorithm in 
terms of number of detected cases and economic 
cost per new case.
Materials and methods
Materials
The laboratory is located at the University Hospital 
of San Juan (Alicante, Spain), a 370-bed suburban 
community hospital belonging to the National 
Public Health System that serves a population of 
234,551 inhabitants, including 9 different primary 
care centers (PCC). It receives samples from inpa-
tients, outpatients and primary care patients.
Venous blood was collected by routine phleboto-
my by expert phlebotomists, according to the rec-
ommendations of the Clinical Laboratory Standard 
Institute (CLSI) (18) in the morning between 8.00-
9.30 AM in every PCC. 
The blood samples were collected into a BD Vacu-
tainer tubes (Becton Dickinson, NJ, USA). After la-
beling, tubes are stored in a cold lock box awaiting 
the refrigerated commercial transport at 10 AM, by 
couriers and delivered to the hospital laboratory 
sample reception desk, where the specimens are 
analyzed and the fasting glucose results are avail-
able before 12.30 PM. Sample transport was moni-
tored by means of our monthly indicators (19). 
Laboratory requests are made electronically from 
the electronic health record system by the GPs 
and the reports are sent out automatically from 
the laboratory information system (LIS) to the pa-
tient’s electronic medical record. 
Methods
We developed an automatic, computer-aided al-
gorithm to identify the samples appropriate to be 
tested for type 2 diabetes and designed a study in 
which HbA1c was measured in such blood sam-
ples from our laboratory. In a first stage, a meeting 
was held between the laboratory professionals 
and the GP coordinator representing the nine 
PCCs to discuss the new indications of HbA1c to 
study a potential methodology and the choice of 
predefined criteria for the design and establish-
ment of a strategy founded in additional HbA1c 
measurement and based in current guidelines (3). 
In a further encounter, the same group conducted 
a retrospective search in the LIS to study how 
many HbA1c would have been added in a one year 
period based on the current guidelines (in ab-
sence of risks factors, HbA1c analysis should be 
performed in patients above 45 years old), to ac-
knowledge the potential strategy cost and the ex-
isting degree of inappropriate request of HbA1c as 
a tool to diagnose type 2 diabetes. In view of the 
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significant number of HbA1c that would have been 
needed to comply with the guidelines, and hence 
the high cost of this potential strategy, the team 
decided not to add the test to every primary care 
patient older than 45, but to perform the follow-
ing strategy: every time a GP requests a cell blood 
count (CBC) (sample availability to measure HbA1c) 
and a fasting glucose to a patient older than 45 
without a prior HbA1c request in the past 3 years, 
the LIS automatically adds such test if glucose val-
ues in the current request are between 5.6 and 6.9 
mmol/L. Additionally, when HbA1c value is ≥ 6.5% 
(48 mmol/mol), the LIS recommends a second 
HbA1c request, through a comment in the labora-
tory report. 
Thereafter, a report was sent to the GPs coordina-
tors of the different PCCs informing about the pro-
posed strategy, and a two months reflection peri-
od was established to communicate the strategy to 
every GP in the 9 different PCCs. In a last meeting, 
this strategy was approved. The study was also ap-
proved by the Hospital Research Committee.
We retrospectively calculated the number of addi-
tional HbA1c that would have been measured dur-
ing the year 2012 if the test would have been pro-
cessed in every primary care patient older than 45 
years with a CBC request and no HbA1c request in 
the current blood sample and in the prior three 
years.
From March 2013 to August 2014, same type of pa-
tients, that additionally presented fasting glucose 
values between 5.6 and 6.9 mmol/L were prospec-
tively identified and were established as the pre-
defined criteria for additional HbA1c measure-
ment. We calculated the number of HbA1c test 
that were indeed automatically added by the LIS 
based on our established strategy, as detailed 
above, and also when was requested by GP (in cer-
tain patients who accomplished all the prior crite-
ria it was the GP that initially had ordered the 
HbA1c). We also counted the number of patients 
detected who fell into the category of ‘increased 
risk for diabetes’ as per ADA HbA1c criteria (HbA1c 
results between 5.7% and 6.4% (39-47 mmol/mol)).
The electronic medical record of every subject 
with an HbA1c result ≥ 6.5% (48 mmol/mol) was 
evaluated by the attending GP and/or a patholo-
gist to investigate whether the HbA1c values could 
have been potentially explained due to medica-
tion, and whether type 2 diabetes was finally con-
firmed or discarded, or if the patient was still wait-
ing to confirm/discard type 2 diabetes. The final 
diagnosis of type 2 diabetes was based on an ad-
ditional HbA1c ≥ 6.5% (48 mmol/mol), fasting glu-
cose ≥ 7.0 mmol/L, or 2 hour glucose after a 75 g 
oral glucose tolerance test ≥ 11.1 mmol/L (3). 
Finally, we calculated the total economic cost per 
patient diagnosed as diabetic, in both groups 
when HbA1c was requested by GP or by means of 
our strategy, taking into account the total number 
of additional HbA1c tests and the cost of reagent 
(1.15€ per HbA1c test; number of performed tests x 
1.15 euros).
Bio-Rad Variant II (www.biorad.com) ion-exchange 
HPLC instrument (NGSP-certified and anchored to 
the Diabetes Control and Complication Trial 
(DCCT) reference study and to the IFCC Reference 
Method), was used to measure HbA1c in whole 
blood. Glucose concentration was measured using 
hexokinase method in a Cobas 8000® Chemistry 
System (Roche Diagnostics, Basel, Switzerland). 
Results
Retrospective analysis
During 2012, the laboratory received requests for 
91,219 primary care patients. 61,955 (67.9%) sub-
jects were older than 45 years. 25,242 (40.7%) pa-
tients did not have an HbA1c requested the previ-
ous 3 years. Among those, the GPs did not order 
simultaneously HbA1c for 17,348 patients (68.8%). 
13,085 (75.4%) had a CBC requested and hence 
sample availability. Figure 1 summarizes the pa-
tient selection.  
The economic cost if in each of those samples 
HbA1c would have been measured was 15,048€. 
Prospective study
In the prospective study, the laboratory received 
requests for 133,399 primary care patients. Figure 
2 summarizes the patient selection. 4342 (3.6%) of 
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these primary care patients were older than 45 
years without a prior HbA1c requested in the past 
three years and a glucose result between 5.6 and 
6.9 mmol/L. In 2250 (51.8%) cases HbA1c was re-
quested by the GPs and 2092 (48.2%) HbA1c were 
added due to our strategy. The total cost of the 
tests added by our algorithm was 2393€.
The results of the HbA1c showed that, 3614 pa-
tients that did not have an HbA1c requested the 
previous 3 years fell into the category of ‘increased 
risk for diabetes’ as per ADA HbA1c criteria (Figure 
2). In 2674, HbA1c was requested by the GPs and in 
940 (26.0%) HbA1c was added due to our strategy.
314 (7.2%) subjects who were older than 45 years 
without a prior HbA1c requested in the past three 
years and a glucose result between 5.6 and 6.9 
mmol/L had HbA1c values ≥ 6.5% (48 mmol/mol). 
After reviewing the medical records, 141 (44.9%) 
were excluded from the analysis: 117 patients were 
already known diabetic (In 109 patients, HbA1c 
was requested by the GPs; in 8 it was added 
through our strategy), 7 were on high dose corti-
costeroids, 6 died before we were able to check 
their medical records, and 11 were residents from 
other health care areas whose medical records 
were not available for review. Of the 173 (55.1%) re-
maining patients, 82 (47.3%) were diagnosed as 
type 2 diabetes, and 24 (13.8%) are still waiting to 
confirm/discard type 2 diabetes, despite our writ-
ten recommendation. Considering those 82 pa-
tients, the first HbA1c was requested by the GPs in 
54 (65.8%) patients, and automatically added by 
the LIS based on our strategy for 28 (34.2%) sub-
jects. This data is illustrated in Figure 3.
Each case of type 2 diabetes diagnosed represent-
ed a cost of 47.5€ when HbA1c was requested by 
GPs and 85.4€ when registered by means of our 
strategy. 
Discussion
Our strategy regarding the automatic addition of 
HbA1c to primary care patients detected new cas-
es of type 2 diabetes that would have had other-
wise remained occult. The cost per new identified 
case was significantly lower than the referred in 
previous studies (12-16). When HbA1c was initially 
requested by the GPs according to the current 
guidelines, the success rate to diagnose of type 2 
diabetes was higher and the cost per new case was 
lower; However, due to the low cost per case, 
cheaper than in other studies, our strategy ap-
pears still payable in spite of almost two times 
more expensive (12-16). Interestingly enough, 37% 
of the abnormal HbA1c values corresponded to al-
ready known diabetic patients; the fact that the 
test was not requested in the previous 3 years, in-
dicates a poor management of the disease. 
The high number of patients detected labeled as 
‘increased risk for diabetes’ as per ADA HbA1c crite-
ria, is of most importance as it enables the GP to 
target strategies to minimize risk of progression to 
type 2 diabetes.
Younger then 45 years
n = 29,264
HbA1c in the past 3 years
n = 36,713
HbA1c requested by GP
n = 7894






in the past 3 years
n = 25,242





Total cost of 15,048€
Figure 1. Flow diagram of patient selection for the pre-inter-
vention retrospective analysis. 
During the year 2012, the laboratory received 91,219 primary 
care requests. 13,085 patients were > 45, did not have an HbA1c 
measured in the past three years or requested in the consid-
ered blood sample, and had blood sample for us to measure 
HbA1c. The hypothetical total economic cost of adding Hb1Ac 
to those patients would have been 15,048€.
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Previous evidence regarding blood spot-based 
measures of glucose homeostasis and type 2 dia-
betes prevalence show that incorporating HbA1c 
and glucose values to blood samples in a nation-
ally representative population of young US adults, 
increased prevalence of type 2 diabetes from 2.9% 
to 6.8% (20). 
The initial retrospective LIS database search served 
to collect information regarding the potential in-
appropriate request of HbA1c to diagnose type 2 
diabetes. Based on this data, and considering the 
high cost, we decided not to systematically regis-
ter HbA1c in all primary care patients above 45 
with no HbA1c the prior three years. In contrast, 
we decided to proceed with the strategy we pro-
pose in this manuscript. At present, we do not 
know how many type 2 diabetes cases would have 
been detected if we had added HbA1c to every pa-
tient older than 45 years without an HbA1c re-
quested in the previous three years, regardless of 
their level of glucose. What we know, is that this 
alternative strategy would have been much more 
expensive. However, each institution may make its 
own decision based on its economic constraints. 
Once test inappropriateness is detected and con-
firmed, there are numerous strategies to achieve a 
proper requesting. Automatic strategies through 
the LIS are very easy to do establish and follow 
Younger then 45 years
n = 42,796
HbA1c in the past 3 years
n = 77,804




HbA1c not requested by GP
Added by our straregy
n = 2092 
HbA1c ≥ 6.5%
n = 77
Glucose < 5.6 or > 6.9 mmol/L
n = 8457

















Figure 2. Flow diagram of patient selection for the post-intervention prospective analysis. 
During the 18 months period, the laboratory received CBC requests for 133,399 patients. 12,799 were > 45 and did not have an HbA1c 
measured in the past three years. 4342 had glucose between 5.6-6.9 mmol/L. The GPs had already requested HbA1c in 2250 of those 
subjects; 2092 were added by the LIS according to our strategy. The total economic cost of adding Hb1Ac to those 2092 patients was 
2393€.
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Figure 3. Flow diagram of patient selection for the 314 patients with an HbA1c above 6.4% (47 mmol/mol) in the post-intervention 
period. 
141 patients were excluded. 173 patients were included in the analysis. 82 were diagnosed as type 2 diabetes (DM). Out of those 82 
patients, the first HbA1c was requested by the GPs in 54 patients, and added by our strategy for 28 subjects. Each case of DM diag-
nosed represented a cost of 47.5€ when HbA1c was requested by GPs and 85.4€ when registered by means of our strategy.
once they are designed (21). Unlike educational or 
administrative strategies (20), the former are auto-
matic and can easily be maintained over time 
without the need of additional resources. 
By applying our strategy a new type 2 diabetes 
case is detected per 75 HbA1c measured, at a cost 
that appears affordable and reasonable, taking 
into account the potential reduction in type 2 dia-
betes complications that may result from an early 
diagnosis and disease management. Previous 
studies highlight the large economic burden of 
type 2 diabetes and its complications on the indi-
vidual and health care system (22). Early detection 
of the disease is vital since it brings the opportuni-
ty for prompt interventions aimed at preventing 
or delaying the progression of the disease and its 
known severe associated complications (23). In 
fact, the largest components of medical expendi-
tures of diagnosed type 2 diabetes for 2012 in the 
United States were hospital inpatient care and pre-
scription medications to treat the complications 
(22). Our intervention would adapt to every set-
ting and population; it is self-regulating and thus 
easy to export. The number of “extra” HbA1c 
would depend on the prior test request. The pro-
posed strategy would not produce any additional 
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expense if the test was requested to detect type 2 
diabetes according to our intervention design. 
When the GPs requested HbA1c to detect type 2 
diabetes, the success in detecting new cases was 
higher. The GPs initially request HbA1c on primary 
care patients, as advised by the guidelines. Addi-
tionally, some other risk factors beyond the guide-
lines may also prompt them to request the test. 
That first step should identify most patients with 
type 2 diabetes. The laboratory, on the other hand, 
dealt with a subgroup of patients; since a signifi-
cant proportion of subjects should have been al-
ready identified by the primary care physicians in 
the prior first round. Hence, the chance of identify-
ing a new case is lower, and therefore the cost per 
patient is higher.
The study has two additional and collateral find-
ings. The fact that some diabetic patients did not 
have HbA1c measured over a period of three years 
suggests that HbA1c was under-requested to fol-
low-up type 2 diabetes, and certain patients were 
not correctly managed. Furthermore, the fact that 
14% of patients with a first HbA1c value ≥ 6.5% (48 
mmol/mol)– a result with meaningful clinical value 
– were ignored in spite of the comment in the lab-
oratory report agrees with previous studies on ig-
nored laboratory results (24,25), indicating that 
more actions are needed to unmask tests results 
with high clinical value (26). 
Our study had certain limitations. First, the strate-
gy was limited to primary care patients with a re-
quest for a CBC. There were patients that did not 
have the chance to participate in this computer-
aided algorithm since they did not had a CBC re-
quest and hence sample availability to measure 
HbA1c. Second, the strategy was too simplified 
and could lead to fact that large proportion of pa-
tients below 45 years old, with risk factors cannot 
be screened with this intervention. Another handi-
cap is that the economic costs of our strategy may 
not apply to other countries, since our laboratory 
belongs to the Public Health Network, where rea-
gent prices are very low. However, the main limita-
tion of our study is that we currently do not know 
how many of the 24 patients that are currently 
waiting for type 2 diabetes confirmation, will be 
diagnosed. Nevertheless, we considered it was 
necessary to communicate the results as soon as 
possible due to their relevance in the detection of 
new cases of type 2 diabetes.
A simple and automated strategy designed in the 
clinical laboratory, in consensus with the request-
ing clinicians, based on the LIS and the American 
Diabetes Association guidelines, detected new 
cases of type 2 diabetes in primary care at a cost of 
85.4€.
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